Navigation Links
Amgen and Peregrine Under StockCall Scrutiny: Pharma Stocks Deal with Drug Developments and Patents
Date:2/6/2013

of its revenue from Neupogen franchise. However, the drug would go off patent protection by the end of 2013 and the loss of exclusivity is expected to affect Amgen. Neupogen faces stiff competition from the companies like Novartis in the markets outside of the U.S. and these competing companies may launch their products in the U.S., causing further damage. However, the company has somewhat strong drug candidates including AMG145, a cholesterol drug candidate.

Amgen stock grew over 25 percent in the past 12 months. It also offers good dividend yield of 2.17 percent. The company is likely to increase its dividend in the future, thus offering good returns to the investors. Amgen is also growing through acquisitions as it recently completed the purchase of Icelandic company decode Genetics.

Peregrine Struggles with Cancer Drug Development

Peregrine Pharmaceuticals Inc. specializes in developing therapies for viral infections. It also develops treatments for cancers. It is currently engaged in developing treatment for non-small cell lung cancer. If successful, the company will make big fortunes as non-small cell lung cancer accounts for about 80 percent of lung cancer cases. However, the company does not have very solid track record. The drug candidate bavituximab has been controversial as it led to the stock's massive tumble in September 2012. Sign up to download the free technical analysis on Peregrine Pharmaceuticals at

http://www.StockCall.com/PPHM020613.pdf  

Peregrine is a small company with the market capitalization of less than $300 million. The stock is quite volatile as well. The company is currently looking to get past the phase II for bavituximab. Overall, the stock may be held if it is already in your portfolio. On the upside, the stock is currently trading about 50 percent below its 52-week high, thus in case of positive news on its
'/>"/>

SOURCE StockCall.com
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014 ... report is available in its catalogue: ... 2014-2024 http://www.reportlinker.com/p02332847/Needle-Free-Delivery-Technology-and-Market-Forecast-2014-2024.html ... – discover technological and commercial prospects What ... delivery market? Visiongain,s brand new report shows ...
(Date:8/28/2014)... Pharmatech initiated enrollment for its AccessPPM ... method for matching cancer patients to cancer clinical ... specific cancers, disease staging, and genetic mutations - ... in the first place. The challenge that the ... be well known to the patient or even ...
(Date:8/28/2014)... 2014 Tianyin Pharmaceutical Co., Inc. (NYSE ... that specializes in patented biopharmaceutical, modernized traditional Chinese ... (API) today updates the timeline for the GMP ... The Company is scheduled to submit ... Food & Drug Administration,s (CFDA) review in the ...
Breaking Medicine Technology:Needle-Free Delivery: Technology and Market Forecast 2014-2024 2Needle-Free Delivery: Technology and Market Forecast 2014-2024 3Needle-Free Delivery: Technology and Market Forecast 2014-2024 4Needle-Free Delivery: Technology and Market Forecast 2014-2024 5Needle-Free Delivery: Technology and Market Forecast 2014-2024 6Needle-Free Delivery: Technology and Market Forecast 2014-2024 7Needle-Free Delivery: Technology and Market Forecast 2014-2024 8Needle-Free Delivery: Technology and Market Forecast 2014-2024 9Needle-Free Delivery: Technology and Market Forecast 2014-2024 10Needle-Free Delivery: Technology and Market Forecast 2014-2024 11Needle-Free Delivery: Technology and Market Forecast 2014-2024 12Needle-Free Delivery: Technology and Market Forecast 2014-2024 13Needle-Free Delivery: Technology and Market Forecast 2014-2024 14Needle-Free Delivery: Technology and Market Forecast 2014-2024 15Needle-Free Delivery: Technology and Market Forecast 2014-2024 16Needle-Free Delivery: Technology and Market Forecast 2014-2024 17Needle-Free Delivery: Technology and Market Forecast 2014-2024 18Enrollment in Pharmatech's Revolutionary AccessPPM Program Launches 2TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2
... The High Court of Germany ( Bundesgerichtshof ) handed ... in its dispute with the Finnish company Medix Biochemica. The ... associated with Medix,s ActimPROM test is null and void due ... to pay AmniSure® an undisclosed amount to be determined by ...
... -- Chindex International, Inc. ("Chindex") (Nasdaq: CHDX ... products and services in the People,s Republic of China, ... results for the three and nine-month periods ended December ... market closes. Management will host a conference call at ...
Cached Medicine Technology:German High Court Rules in Favor of AmniSure® as New European Guidelines Published 2Chindex International to Report Financial Results for the Three and Nine-Month Periods Ended December 31, 2010 2
(Date:8/29/2014)... Food and Drug Administration (FDA)-approved treatment for decreasing ... effective at reducing fracture risk as other current ... loss. With the use of wide- and small-angle ... out experiments at the U.S. Department of Energy,s ... Laboratory that revealed an additional mechanism underlying raloxifene ...
(Date:8/29/2014)... Francisco, CA (PRWEB) August 30, 2014 ... 10 best web conference providers in the online service ... the list were global leaders Webex, GotoMeeting and Infinite. ... the industry users have to determine which provider is ... Essentially, web conference businesses search for compelling consumer goods ...
(Date:8/29/2014)... 2014 The 8th Annual Paint Columbus Pink® ... a Cause, Pink Pooch Contest, Light of Life Ceremony, Power ... Pink Bow Campaign – all in support of cancer awareness. ... this year…. Paint Columbus Pink Foam and Obstacle Challenge on ... 727 54th Street, Columbus, Georgia 31904. It will be the ...
(Date:8/29/2014)... 29, 2014 After having a double ... had to have breast reconstruction. She found that the ... she decided that there needed to be a solution. ... a woman or man who needs or wants breast ... promotes confidence and peace of mind. Producible in design ...
(Date:8/29/2014)... 2014 University of Western States (UWS), ... announced that Daniel Redwood, DC, director of the human ... the Year,” by the Missouri State Chiropractors Association (MSCA) ... , Patrick Montgomery, DC, president of the MSCA, cited ... Missouri House Task Force for Medicaid Reform, in bringing ...
Breaking Medicine News(10 mins):Health News:Revealing a novel mode of action for an osteoporosis drug 2Health News:Top10InAction Reveals Best Web Conference Providers 2Health News:Paint Columbus Pink Cancer Awareness/Kick-Off Meeting for Anyone Interested in Participating 2Health News:University of Western States Director of Human Nutrition and Functional Medicine Daniel Redwood, DC, named Missouri Educator of the Year by MSCA 2
... June 03, 2010 The John Theurer Cancer Center ... physicians and researchers will present 16 abstracts on treatment ... during the Annual Meeting of American Society of Clinical ... "At the John Theurer Cancer Center, we,re ...
... Americans now have choices ... treatment in the USA, Medical Tourism is the answer. , ... Carlsbad, CA (PRWEB) June 2, 2010 – Website promotes the healthcare options ... USA. , , ,Global Medical Connect is a one stop medical tourism shop to take care ...
... , THURSDAY, June 3 (HealthDay News) -- Fatal medication ... of the inexperience of new medical residents, a new ... July, and those first weeks may be a dangerous ... the University of California, San Diego. , The ...
... say it,s not always that simple, , THURSDAY, June 3 ... in many a parent. But having to incorporate information ... make an already sensitive subject even more complicated. , Yet ... As assisted reproduction technology, in which someone other than the ...
... ... Lake Host Malaria Awareness Soccer Clinic this Thursday for Local Youth as part of White ... ... the United Nations Foundation ’s Nothing But Nets campaign are teaming up to raise ...
... ... research study that provides detailed analyses on health plans’ coverage and management of ... ... Pharmaceuticals Service is an ongoing market research study that provides detailed analyses on ...
Cached Medicine News:Health News:Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO 2Health News:Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO 3Health News:Global Medical Connect Launches New Website for the Growing Medical Tourism Industry 2Health News:Donor-Assisted Conception Sparks Disclosure Dilemmas 2Health News:Donor-Assisted Conception Sparks Disclosure Dilemmas 3Health News:Real Salt Lake Teams Up with Nothing But Nets to Fight Malaria 2Health News:Real Salt Lake Teams Up with Nothing But Nets to Fight Malaria 3Health News:HIRC Research Alert: Health Plans Expected to Increase Adoption of Percent Copays to Manage Specialty Medications 2Health News:HIRC Research Alert: Health Plans Expected to Increase Adoption of Percent Copays to Manage Specialty Medications 3
On the wards, on rounds, or at the bedside, clinicians can instantly access authoritative, up-to-date, practical guidelines for the immediate and long-term medical and surgical management of all card...
... Diagnosis & Treatment in Cardiology provides ... and manage patients with cardiac diseases. ... 200 cardiac diseases, each reviewed with ... pertinent information including: differential diagnosis, treatment, ...
... those involved with healthcare decisions to keep ... evidence in their field of interest - ... as the volume of evidence increases. Cochrane ... best single source available for continually updated ...
... Cochrane Reviews enable all those involved with ... with the very latest evidence in their ... becomes harder each year as the volume ... problem by delivering the best single source ...
Medicine Products: